Breast, Ovarian, and Pancreatic Guidelines V.1.2022: Released August 11th, 2021
- The overall document was reorganized to help make it easier to find what you are looking for. Some highlights include:
- ‘Principles of Cancer Risk Assessment and Counseling’ section was moved to the beginning (pages EVAL-A 1 to 7)
- Testing criteria were substantially reorganized and put into a table format, divided into general criteria relevant to all cancers and cancer-specific criteria (starts on page Crit-1)
- Testing based on PARP inhibitor eligibility for earlier stage/high-risk BRCA-associated breast cancers (based on OlympiA trial results) was incorporated (page Crit-2)
- In recognition that many other NCCN guidelines include inherited cancer content, a list of guidelines was compiled that include a ‘Principles’ section, testing indications, and/or cancer risk management (bottom of page Crit-1)
- Gene-A table was updated as follows:
- The information and order were revised to include absolute risk, management, and strength of evidence
- Where available, type of breast cancer (or over-representation of specific type) was included
- CDH1 – added ‘discussion of option for risk-reducing mastectomy’
- Lynch Syndrome genes – ovarian cancer risks updated by gene
- STK11 – clarified that ovarian cancer risk is for non-epithelial (sex cord) tumors
- Added Gene-B table to list information on autosomal recessive conditions related to the inherited cancer genes listed in Gene-A table
Colorectal Cancer Guidelines V.1.2021: Released May 11th, 2021
- Lynch Syndrome: Extensive updates to cancer risks among individuals with Lynch Syndrome (specified by gene – MLH1, MSH2, MSH6, PMS2, EPCAM)
- Familial Adenomatous Polyposis: extensive revisions to duodenal findings and management
- Peutz-Jeghers Syndrome: section extensively revised
- Juvenile Polyposis Syndrome: section extensively revised
- Gene table (Table 3 – starting on page GENE-3) updated and revised
Check out the full NCCN guidelines by creating a FREE account at www.nccn.org